These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. Groot C; Cicognola C; Bali D; Triana-Baltzer G; Dage JL; Pontecorvo MJ; Kolb HC; Ossenkoppele R; Janelidze S; Hansson O Alzheimers Res Ther; 2022 May; 14(1):67. PubMed ID: 35568889 [TBL] [Abstract][Full Text] [Related]
26. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. Lantero-Rodriguez J; Vrillon A; Fernández-Lebrero A; Ortiz-Romero P; Snellman A; Montoliu-Gaya L; Brum WS; Cognat E; Dumurgier J; Puig-Pijoan A; Navalpotro-Gómez I; García-Escobar G; Karikari TK; Vanmechelen E; Ashton NJ; Zetterberg H; Suárez-Calvet M; Paquet C; Blennow K Alzheimers Res Ther; 2023 Mar; 15(1):48. PubMed ID: 36899441 [TBL] [Abstract][Full Text] [Related]
28. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616 [TBL] [Abstract][Full Text] [Related]
29. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M; JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873 [TBL] [Abstract][Full Text] [Related]
30. Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease. Yang CC; Chiu MJ; Chen TF; Chang HL; Liu BH; Yang SY J Alzheimers Dis; 2018; 61(4):1323-1332. PubMed ID: 29376870 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H; Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600 [TBL] [Abstract][Full Text] [Related]
32. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Mielke MM; Aakre JA; Algeciras-Schimnich A; Proctor NK; Machulda MM; Eichenlaub U; Knopman DS; Vemuri P; Graff-Radford J; Jack CR; Petersen RC; Dage JL Alzheimers Dement; 2022 Apr; 18(4):602-611. PubMed ID: 34310832 [TBL] [Abstract][Full Text] [Related]